Nixi Laboratories Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 9.90 Cr
as on 16-11-2024
- Company Age 8 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 12.33 Cr
as on 16-11-2024
- Revenue -30.25%
(FY 2023)
- Profit -79.53%
(FY 2023)
- Ebitda -20.77%
(FY 2023)
- Net Worth 5.80%
(FY 2023)
- Total Assets 3.00%
(FY 2023)
About Nixi Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 9.90 Cr.
The company currently has active open charges totaling ₹12.33 Cr.
Paresh Bagadia, Sanjeev Kumar, Harmanpreet Singh, and One other member serve as directors at the Company.
- CIN/LLPIN
U24100HP2016PTC001167
- Company No.
001167
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Mar 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Himachal Pradesh
Industry
Company Details
- Location
Sirmaur, Himachal Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Nixi Laboratories Private Limited offer?
Nixi Laboratories Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antifungal Injection, Tablet & Syrup.
Who are the key members and board of directors at Nixi Laboratories?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjeev Kumar  | Whole-Time Director | 08-Mar-2016 | Current |
| Paresh Bagadia | Director | 01-Mar-2021 | Current |
| Harmanpreet Singh | Director | 08-Mar-2016 | Current |
| Aditya Gupta | Director | 01-Mar-2021 | Current |
Financial Performance of Nixi Laboratories.
Nixi Laboratories Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 30.25% decrease. The company also saw a substantial fall in profitability, with a 79.53% decrease in profit. The company's net worth moved up by a moderate rise of 5.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nixi Laboratories?
In 2023, Nixi Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 24 Nov 2017 | ₹12.33 Cr | Open |
How Many Employees Work at Nixi Laboratories?
Nixi Laboratories has a workforce of 27 employees as of Jul 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nixi Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nixi Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
